The Harvoni® medicinal product came in the market of the Republic of Kazakhstan26 October
Dear patients and healthcare professionals, we are pleased to inform you that the Harvoni® medicinal product (RK-LS-5№22460 dated 02.11.2016) came in the market of the Republic of Kazakhstan and became available to the patients for treatment of hepatitis C.
Viva Pharm LLP is the official representative of Gilead Sciences Inc., the American biopharmaceutical company, the developer and manufacturer of innovative medicinal products that focuses on antiviral drugs used in the treatment of HIV, hepatitis B and hepatitis C (among them Viread®, Truvada®, Harvoni®, and Sovaldi®).
Harvoni® (somosbuvir/lepidasvir)* is a combination drug, in tablet form, for the treatment of genotype 1 chronic Hepatitis C (HCV) virus. The treatment regimen of Harvoni® does not require the administration of interferon or ribavirin approved by the FDA for the treatment of hepatitis.
*It is a prescription medicine.